Alliance Pharma PLC Half Year Trading Update (5237E)
July 19 2016 - 2:00AM
UK Regulatory
TIDMAPH
RNS Number : 5237E
Alliance Pharma PLC
19 July 2016
For immediate release 19 July 2016
ALLIANCE PHARMA PLC
("Alliance" or the "Group")
Half Year Trading Update
Alliance Pharma plc (AIM: APH), the specialty pharmaceutical
company, announces its pre-close trading update ahead of the
announcement of its interim results for the six months ended 30
June 2016.
The Group performed well and in line with the Board's
expectations with sales more than doubling to GBP46.4m (2015:
GBP22.8m), following the Group's transformational acquisition of
the Sinclair Healthcare Products business in December 2015. The
Sinclair products contributed sales of GBP20.6m.
Our three key growth brands performed in line with expectations
with our largest-selling brand, Kelo-cote(TM), acquired from
Sinclair in December 2015, achieving sales of GBP4.1m. Hydromol(TM)
maintained strong sales growth of 10% in the first half with sales
of GBP3.5m for the six month period. Our ophthalmology product,
MacuShield(TM), acquired in February 2015, delivered GBP2.0m in the
first half versus GBP1.4m in the first five months post-acquisition
in February 2015.
The integration of the Sinclair products under the Alliance name
is progressing well. Activities relating to finance and operations
are expected to be largely complete by the end of the third quarter
this year and product transfers in the countries are proceeding in
line with local regulatory timelines.
It is too early to assess the long-term impact of the UK's
decision to leave the European Union, although, having operations
in France, Germany, Italy and Spain, we do not anticipate any
issues over market access. Additionally, we do not expect to be
adversely affected by the current sterling exchange rate
volatility. Indeed, if current exchange rates prevail we would
expect a modest benefit to our sales and financial performance as
we expect trading volumes to continue in line with expectations
throughout 2016.
Alliance's interim results for the six months ended 30 June 2016
are scheduled to be released on 14 September 2016.
For further information:
Alliance Pharma plc + 44 (0) 1249 466966
John Dawson, Chief Executive
Andrew Franklin, Chief Financial
Officer
Sarah Robinson, Company Secretary
www.alliancepharma.co.uk
+ 44 (0) 20 7466
Buchanan 5000
Mark Court / Sophie Cowles
/ Jane Glover
+ 44 (0) 20 7260
Numis Securities Limited 1000
Nominated Adviser: Michael
Meade / Freddie Barnfield
Corporate Broking: James
Black / Toby Adcock
Notes to editors:
About Alliance Pharma
Alliance, founded in 1998, is an international specialty
pharmaceutical company based in Chippenham, Wiltshire, UK. The
Company has sales in more than 100 countries worldwide via direct
sales, joint ventures and a network of distributors. Alliance has a
strong track record of acquiring the rights to established niche
products and it currently owns or licenses the rights to
approximately 90 pharmaceutical and consumer healthcare products.
The Company continues to explore opportunities to expand its
product portfolio.
Alliance joined the AIM market of the London Stock Exchange in
December 2003 and trades under the symbol APH.
This information is provided by RNS
The company news service from the London Stock Exchange
END
TSTSFDFMAFMSELW
(END) Dow Jones Newswires
July 19, 2016 02:00 ET (06:00 GMT)
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Apr 2023 to Apr 2024